Abstract
Aim: To determine the criteria considered important by Dutch rheumatologists in judging whether a patient with ankylosing spondylitis should start tumour necrosis factor (TNF) blocking therapy.
Methods: 19 Dutch rheumatologists were asked to prioritise various demographic and clinical features for their importance in judging whether a patient should be treated with TNF blocking therapy. In addition, nine Dutch physicians who had referred patients with ankylosing spondylitis for inclusion in an ongoing long term observational study (OASIS) were asked to determine on the basis of case record review for each of their patients whether or not TNF blocking therapy would be considered appropriate.
Results: The variables considered most important were: rate of development of functional impairment; physician's global assessment of current disease activity; physician's global assessment of cumulative disease activity; presence of hip arthritis; physician's global assessment of disease severity. Analysis of the OASIS data (79 patients) showed that patients in whom TNF blocking therapy was considered justified (n = 24; 30%) differed significantly from those in whom it was not considered justified in: patient reported disease activity; functional impairment; spinal mobility; radiographic damage score. Multivariate analysis showed that male sex, function, and radiographic damage were the only independent determinants of a decision to start TNF blocking drugs.
Conclusions: Physicians reported that disease activity, function, and severity were critically important in judging whether to start TNF blocking therapy. In practice, they based their decision more on severity than on activity. They were able to select patients with a high level of radiographic damage, which suggests that this feature captures other domains such as disease activity, spinal mobility, and function.
Full Text
The Full Text of this article is available as a PDF (227.5 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., Gromnica-Ihle E., Kellner H., Krause A., Schneider M. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002 Apr 6;359(9313):1187–1193. doi: 10.1016/s0140-6736(02)08215-6. [DOI] [PubMed] [Google Scholar]
- Gorman Jennifer D., Sack Kenneth E., Davis John C., Jr Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002 May 2;346(18):1349–1356. doi: 10.1056/NEJMoa012664. [DOI] [PubMed] [Google Scholar]
- Spoorenberg A., van der Heijde D., de Klerk E., Dougados M., de Vlam K., Mielants H., van der Tempel H., van der Linden S. A comparative study of the usefulness of the Bath Ankylosing Spondylitis Functional Index and the Dougados Functional Index in the assessment of ankylosing spondylitis. J Rheumatol. 1999 Apr;26(4):961–965. [PubMed] [Google Scholar]
- Spoorenberg A., van der Heijde D., de Klerk E., Dougados M., de Vlam K., Mielants H., van der Tempel H., van der Linden S. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol. 1999 Apr;26(4):980–984. [PubMed] [Google Scholar]
- van Tubergen A. M., Landewé R. B., van der Linden S. Spondylarthropathies: options for combination therapy. Springer Semin Immunopathol. 2001;23(1-2):147–163. doi: 10.1007/s002810100064. [DOI] [PubMed] [Google Scholar]
- van Tubergen A., Landewé R., van der Heijde D., Hidding A., Wolter N., Asscher M., Falkenbach A., Genth E., Thè H. G., van der Linden S. Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum. 2001 Oct;45(5):430–438. doi: 10.1002/1529-0131(200110)45:5<430::aid-art362>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
- van der Heijde D., Braun J., McGonagle D., Siegel J. Treatment trials in ankylosing spondylitis: current and future considerations. Ann Rheum Dis. 2002 Dec;61 (Suppl 3):iii24–iii32. doi: 10.1136/ard.61.suppl_3.iii24. [DOI] [PMC free article] [PubMed] [Google Scholar]
- van der Heijde D., Calin A., Dougados M., Khan M. A., van der Linden S., Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol. 1999 Apr;26(4):951–954. [PubMed] [Google Scholar]